Contact Supplier

Contact Supplier

To get in touch with SIRION Biotech GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    SIRION Biotech GmbH licensed its LentiBOOST™ transduction technology to Cellectis

    news-releasesSIRION Biotech GmbH
    February 3rd 2021

    Munich, Germany and Cambridge, Mass Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

    Allogeneic CAR-T cell therapy represent a future-defining shift in simplicity, availability, and cost efficiency of immune-oncology approaches. Engineering effective allogeneic T-cells, in contrast to patient derived cells, elevates the technology to the level of a realistic off-the-shelf product.

    Dr. Christian Thirion, CEO and founder of SIRION explains: “LentiBOOST™ improves lentiviral transduction of difficult cell types like hematopoietic stem cells, and in addition generates stable integration of large constructs generally needed to generate CAR-T cells.”

    “We are delighted that our product will help further develop affordable allogeneic cancer treatments that will, once approved, benefit patients with unmet needs” says SVP BD & Licensing, Dr. Sabine Ott.

    About SIRION Biotech
    SIRION Biotech began its customer business in 2007 in Munich, setting their goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccination development. This meant building novel, all-encompassing viral vector platforms for lenti-, adeno-, and adeno-associated viruses which expedite its partners’ advances in drug, cosmetics, and food industries. To date SIRION has completed over 1500 projects of all sizes, working closely with over 200 independent customer groups from academia and industry.

    Corporate Contact
    Dieter Lingelbach, COO
    SIRION Biotech
    +49 89-700-96199-14

    Media Contact USA
    Lisa DeScenza
    Vice President, Integrated Communications
    (978) 395-5970

    BD & Licensing Contact
    Sabine Ott, Ph.D., Senior VP Licensing & BD
    SIRION Biotech
    +49 89-700-96199-13

    Succeed with Sirion

    LentiBOOST® - Lentiviral Transduction Enhancer For Clinical Applications

    SIRION Biotech GmbH licensed its LentiBOOST™ transduction technology to Cellectis

    Contact SIRION Biotech GmbH

    Simply fill out the form below to contact SIRION Biotech GmbH now.

    Send SIRION Biotech GmbH a Message